title: Inhibition of cytochrome P450 activity enhances the systemic availability of triclabendazole metabolites in sheep.
abstract: Understanding the disposition kinetics and the pattern of metabolism is critical to optimise the flukicidal activity of triclabendazole (TCBZ) in ruminants. TCBZ is metabolised by both flavin-monooxygenase (FMO) and cytochrome P450 (P450) in the liver. Interference with these metabolic pathways may be useful to increase the systemic availabilities of TCBZ metabolites, which may improve the efficacy against Fasciola hepatica. The plasma disposition of TCBZ metabolites was evaluated following TCBZ co-administration with FMO [methimazole (MTZ)] and P450 [piperonyl butoxyde (PB) and ketoconazole (KTZ)] inhibitors in sheep. Twenty (20) healthy Corriedale x Merino weaned female lambs were randomly allocated into four experimental groups. Animals of each group were treated as follow: Group A, TCBZ alone (5 mg/kg, IV route); Group B, TCBZ (5 mg/kg, IV) + MTZ (3 mg/kg, IV); Group C, TCBZ (5 mg/kg, IV) + PB (30 mg/kg, IV) and Group D, TCBZ (5 mg/kg, IV) + KTZ (10 mg/kg, orally). Blood samples were taken over 240 h post-treatment and analysed by HPLC. TCBZ sulphoxide and sulphone were the main metabolites recovered in plasma. MTZ did not affect TCBZ disposition kinetics. TCBZ sulphoxide Cmax values were significantly increased (P < 0.05) after the TCBZ + PB (62%) and TCBZ + KTZ (37%) treatments compared to those measured in the TCBZ alone treatment. TCBZ sulphoxide plasma AUCs were higher (P < 0.05) in the presence of both PB (99%) and KTZ (41%). Inhibition of TCBZ P450-mediated oxidation in the liver accounted for the increased systemic availability of its active metabolite TCBZ sulphoxide. This work contributes to the search of different strategies to improve the use of this flukicidal drug in ruminants.
authors.affiliation: Laboratorio de Farmacología, Dpto. de Fisiopatología, Facultad de Ciencias Veterinarias, UNCPBA, Tandil, Buenos Aires, Argentina. gvirkel@vet.unicen.edu.ar
authors.forename: G
authors.initials: G
authors.lastname: Virkel
authors.forename: A
authors.initials: A
authors.lastname: Lifschitz
authors.forename: J
authors.initials: J
authors.lastname: Sallovitz
authors.forename: M
authors.initials: M
authors.lastname: Ballent
authors.forename: S
authors.initials: S
authors.lastname: Scarcella
authors.forename: C
authors.initials: C
authors.lastname: Lanusse
mesh_terms: D000818:Animals; D000831:Animals, Newborn; D000871:Anthelmintics / Q000097:blood / Q000493:pharmacokinetics*; D019540:Area Under Curve; D001562:Benzimidazoles / Q000097:blood / Q000493:pharmacokinetics*; D001682:Biological Availability; D002851:Chromatography, High Pressure Liquid / Q000379:methods / Q000662:veterinary; D065607:Cytochrome P-450 Enzyme Inhibitors; D005260:Female; D007654:Ketoconazole / Q000494:pharmacology; D008713:Methimazole / Q000494:pharmacology; D010882:Piperonyl Butoxide / Q000494:pharmacology; D011897:Random Allocation; D012756:Sheep / Q000097:blood / Q000378:metabolism*; D000077682:Triclabendazole
chemical_list: D000871:Anthelmintics; D001562:Benzimidazoles; D065607:Cytochrome P-450 Enzyme Inhibitors; D000077682:Triclabendazole; D008713:Methimazole; D010882:Piperonyl Butoxide; D007654:Ketoconazole